Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today reported financial results for the third quarter of 2018. (All dollars U.S. unless otherwise noted.) The Company recorded net income of approximately $1.8 million ($0.01 per...
Read More
Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that the Company has elected to issue 3,963,988 common shares of the Company (“Common Shares”) to The Salzman Group in payment of invoices issued under...
Read More
Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced a major step forward in its program to develop the first cannabinoid-derived pain treatment targeting activation of alpha3 glycine receptors. When activated, the alpha3 glycine...
Read More
Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB:KALTF) (the "Company" or "Kalytera") today announced that it has granted stock options on September 24, 2018 to certain directors and employees of the Company. The stock options have an exercise price of...
Read More
Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today provided an update on its lead product development program evaluating cannabidiol (“CBD”) for the prevention and treatment of acute graft versus host disease (“GVHD”). GVHD is...
Read More
Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB:KALTF) (the "Company" or "Kalytera") today reported financial results for the second quarter of 2018. (All dollars U.S. unless otherwise noted.) The Company recorded net income of approximately $5.9 million ($0.04 per Common...
Read More
Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB:KALTF) (the "Company" or "Kalytera") today provided an update on the previously announced arrangements reached with the former shareholders of Talent Biotechs Ltd. of Israel ("Talent") modifying the Company's obligation to make certain...
Read More
Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that the Company has elected to issue 5,657,957 common shares of the Company (“Common Shares”) to The Salzman Group in payment of invoices issued under...
Read More
Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws. Kalytera Therapeutics, Inc. (TSX Venture: KALY) (OTCQB:KALTF) (the “Company” or “Kalytera”)...
Read More
Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws. Kalytera Therapeutics, Inc. (TSX Venture: KALY) (OTCQB:KALTF) (the “Company” or “Kalytera”)...
Read More